What happened

Shares of Veea Inc. (NASDAQ: VEEA) rocketed about 82% in Wednesday's trading on heavy volume of roughly 38 million shares — and that's on top of a roughly 149% surge the session before (from a $2.29 close to around $5.71). Zoom out and it gets wilder: this was a sub-$0.20 stock in late August. In about three weeks it has gone up many times over.

Why it moved

The trigger is a deal. After Monday's close, Veea and Amsterdam-based NovaGen Group B.V. said they'd signed a term sheet to combine and launch "NovaGen Health Networks" — a platform bolting Veea's edge computing and cybersecurity onto NovaGen's cellular-reprogramming and longevity science. A UAE firm, GeoNova Capital, signed a separate term sheet to put in an initial $10 million. Management pegs the combined company at roughly $750 million.

Here's the catch the headline hides: it's all non-binding. The companies are still "targeting execution of a definitive business combination agreement within the coming weeks," and the release states plainly that the deal is subject to definitive documentation and closing conditions. The $750M figure is management's own estimate built on internal projections — not a price anyone actually paid.

Is it expensive?

There's no P/E to quote, because Veea doesn't make money. It booked just $0.14 million of net sales in 2024 (2023's $9.07M was mostly a one-off software licence), lost $15.3 million from operations in the first nine months of FY25, and carries an accumulated deficit of $219.6 million (SEC 10-Q). With about 50 million shares, a ~$5.70 price is roughly a $290M market value sitting on near-zero revenue.

Put that next to a real edge peer. Akamai (NASDAQ: AKAM) makes the same "computing at the edge" pitch, but with about $4.5 billion of revenue, actual profits (~$6.40–7.05 EPS guided this year) and a ~$19.5B market cap at a P/E near 40. Veea is being valued on a story; Akamai on earnings. That gap is the trade.

The business

Veea (founded 2014, New York) sells edge hardware and its VeeaONE platform — connectivity, computing, security and storage in one hub — and holds 120-plus patents. That's the part with real customers today. NovaGen is the moonshot: a longevity outfit whose "ARC Prometheus" process reprograms a patient's own skin cells. Wednesday's spike is about the promise of stapling these two together, not a business that's already earning it.

Who it touches

• Momentum traders: a low-float, headline-driven micro-cap like this swings violently both ways.
• The "longevity" theme: attention here tends to spill into other small regenerative-medicine and digital-health names.
• Existing Veea holders: enjoy the pop, but the edge business itself didn't change this week.

What to watch

One thing decides it: does the term sheet turn into a signed, definitive merger agreement, with GeoNova's money actually wired? If yes, the longevity story gets real scaffolding. If the talks stall or fall apart, there's very little underneath a stock that traded in pennies a month ago — and the round-trip could be ugly.

As of pre-market trading, 16 Sep 2026 (ET). Sources: GlobeNewswire (company release), StockTitan. For discussion and education only — not investment advice. Verify before acting.